The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Daiichi Sankyo's 2012 sales performance.
Meanwhile, Daiichi Sankyo has said it will concentrate on first-line use of quizartinib after being turned down by regulators in Europe and the US, and says it recently completed enrolment ... There are differences between the two drugs, as quizartinib
Competition in the HER2 category is heating up though, with a new antibody-drug conjugate from Daiichi Sankyo and AstraZeneca – trastuzumab deruxtecan – angling for approval in the US in the second
Could add to AZ's portfolio of emerging cancer drugs. AstraZeneca and Daiichi have picked up a priority review from the FDA for their breast cancer therapy trastuzumab deruxtecan, setting up ... Analysts’ expectations for sales potential vary,
Looking to build its momentum in oncology even further, AstraZeneca recently signed a huge $6.9bn deal with Daiichi-Sankyo to develop and co-market its next-generation challenger to
The positive recommendation puts Astellas even further in the lead in front of Daiichi Sankyo – its candidate for FLT3-positive AML was rejected by the FDA earlier this year following misgivings
[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]
Transforming the way health brands and companies communicate, we deliver creative science led, insight-driven solutions that give award winning results...